Royal Bank Of Canada Monopar Therapeutics Transaction History

Royal Bank Of Canada

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$0.31 - $1.35 $31 - $135	100 New	100 $0
Q1 2024 May 15, 2024	BUY	$0.31 - $1.35 $31 - $135	100 New	100 $0
Q1 2023 May 15, 2023	BUY	$1.39 - $3.73 $6,949 - $18,650	5,000 New	5,000 $6,000
Q3 2021 Nov 15, 2021	SELL	$4.5 - $6.0 $4,563 - $6,084	-1,014 Reduced 19.77%	4,116 $20,000
Q2 2021 Aug 16, 2021	BUY	$5.05 - $6.49 $25,906 - $33,293	5,130 New	5,130 $30,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $464M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.